Study to Assess AFM24 in Advanced Solid Cancers

Summary

AFM24-101 is a first in human Phase 1/2a open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies. AFM24 is a tetravalent bispecific (anti-human EGFR x anti-human CD16A) innate immune cell engaging recombinant antibody being developed to target EGFR-expressing solid tumors and has been designed to specifically utilize the cytotoxic potential of the innate immune system, in particular natural killer cells and macrophages for the specific and efficient elimination of EGFR expressing cancer cells.

Timeline

Start

2020-04-07

Primary completion

2023-07-12

Completion

2024-06-24

Outcome

Outcome not reported

Stopped (Enrollment): “Enrollment into expansion cohorts in Phase 2 part was terminated due to sponsor decision”

Drugs

Indications